| 非小细胞肺癌患者血清miR-195的表达及其临床意义 |
| |
| 引用本文： | 蔡静,候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419. DOI: 10.11904/j.issn.1002-3070.2018.05.006 |
| |
| 作者姓名： | 蔡静 候玥 |
| |
| 作者单位： | 成都市龙泉驿区第一人民医院肿瘤血液科(成都 610100) |
| |
| 基金项目： | 2016年成都市龙泉驿区第一人民医院院内项目(编号:201606) |
| |
| 摘 要： | 目的 探讨血清miR-195在非小细胞肺癌(NSCLC)患者中的表达及其临床意义。方法 采用实时荧光定量PCR(qRT-PCR)检测100例非小细胞肺癌患者和90例正常健康体检者血清miR-195的表达量,结合临床资料分析其表达在临床中的作用和意义。结果 与正常人群相比,NSCLC患者血清miR-195相对表达量降低(7.26±1.61 vs. 4.52±1.17,P＜0.01);Ⅲ~Ⅳ期NSCLC患者血清miR-195相对表达量低于Ⅰ~Ⅱ期患者,有淋巴结转移的NSCLC患者血清miR-195相对表达量低于无淋巴结转移者,有远处转移的NSCLC患者血清miR-195相对表达量低于无淋巴结转移者,差异均有统计学意义(P＜0.05),而血清miR-195相对表达量在鳞癌和腺癌患者中无统计学差异,在高分化、中分化、低分化患者中也无统计学差异;Logistic回归分析结果显示,miR-195相对表达量(OR=0.526,95%CI:0.415~0.697,P=0.007)与NSCLC密切相关;血清miR-195相对表达量诊断NSCLC的AUC为0.875(95% CI:0.826~0.923,P=0.004);血清中高表达miR-195的NSCLC患者中位生存时间明显长于血清中低表达miR-195者(P＜0.05),多因素分析表明血清miR-195相对表达量是NSCLC预后的独立影响因素(HR=0.615,95%CI:0.324~0.783;P=0.011)。结论 NSCLC患者血清miR-195表达量降低,并且与NSCLC的分期、淋巴转移、远处转移和预后关系密切,血清miR-195有望成为NSCLC潜在的早期诊断、预后评价的分子标志物。
|
| 关 键 词： | miR-195 非小细胞肺癌 血清 |
| 收稿时间： | 2018-05-21 |
The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer |
| |
| CAI Jing,HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer[J]. Journal of Practical Oncology, 2018, 32(5): 415-419. DOI: 10.11904/j.issn.1002-3070.2018.05.006 |
| |
| Authors: | CAI Jing HOU Yue |
| |
| Affiliation: | Department of Oncology,The First People′s Hospital of Longquanyi District,Chengdu 610100,China |
| |
| Abstract: | Objective The aim of this study was to explore the expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer(NSCLC).Methods Real-time quantitative PCR(qRT-PCR)was used to detect the expression of serum miR-195 in 100 patients with NSCLC and 90 normal healthy subjects.The clinical significance and significance of its expression in clinical analysis were analyzed.Results Compared with the healthy control group(4.52±1.17),the relative expression of serum miR-195 was decreased in patients with NSCLC(7.26±1.61)(P＜0.01).The relative expression of serum miR-195 in patients with Ⅲ~Ⅳ phase of NSCLC was lower than that in patients with I-II phase of NSCLC.The relative expression of serum miR-195 in patients with lymph node metastasis was lower than that in patients without lymph node metastasis.The relative expression of serum miR-195 in patients with distant metastasis was lower than that in patients without lymph node metastasis.They showed a significant difference(P＜0.05).However,the relative expression of serum miR-195 was not statistically different in patients between squamous cell carcinoma and adenocarcinoma,and there was no statistical difference in highly differentiated,moderately differentiated,and poorly differentiated patients.Logistic regression analysis showed that serum miR-195 was significantly correlated with NSCLC(OR=0.526,95%CI:0.415~0.697,P=0.007).Area under ROC(AUC)of serum miR-195 was 0.875(95%CI:0.826~0.923,P=0.004)for the diagnosis of NSCLC.In addition,the NSCLC patients in the high miR-195 expression group was significantly longer the overall survival time than that of patients with low expression of miR-195 in serum(P＜0.05).Multivariate analysis showed that the serum miR-195 expression was an independent influence factor for NSCLC(HR=0.615,95%CI:0.324~0.783,P=0.011).Conclusion The expression of serum miR-195 is decreased in patients with NSCLC,and it is closely related to staging,lymphatic metastasis,distant metastasis and prognosis of NSCLC.Serum miR-195 is expected to be a molecular marker for potential early diagnosis and prognosis evaluation of NSCLC. |
| |
| Keywords: | MiR-195 Non-small cell lung cancer Serum |
|
| 点击此处可从《实用肿瘤学杂志》浏览原始摘要信息 |
|
点击此处可从《实用肿瘤学杂志》下载免费的PDF全文 |
|
